Study of LYL314 in Aggressive Large B-Cell Lymphoma
Phase 1/2
270
about 8.1 years
18+
30 sites in CA, CO, GA +16
What this study is about
Researchers are testing a new treatment called LYL314 for people with aggressive large B-cell lymphoma. The trial will evaluate the safety and effectiveness of this treatment, which targets CD19 and CD20 cells.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Cyclophosphamide
- 2.Take Fludarabine
- 3.Take LYL314
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), fludarabine
infusion
Primary: Phase 1: Evaluate the safety and tolerability of a single dose of ronde-cel administered as a single agent, Phase 2: Estimate the efficacy of ronde-cel, as measured by overall response rate (ORR)
Secondary: Phase 1: Evaluate the pharmacokinetics of ronde-cel when administered as a single agent, Phase 2: Evaluate the pharmacokinetics of ronde-cel when administered as a single agent, Phase 2: Evaluate the safety and tolerability of a single dose of ronde-cel administered as a single agent
Oncology